- Home
- CUE vs KORE Comparison
CUE vs KORE Comparison
Compare CUE & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- KORE
- Stock Information
- Founded
- CUE 2014
- KORE 2003
- Country
- CUE United States
- KORE United States
- Employees
- CUE N/A
- KORE N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- CUE Health Care
- KORE Consumer Discretionary
- Exchange
- CUE Nasdaq
- KORE Nasdaq
- Market Cap
- CUE 48.0M
- KORE 39.3M
- IPO Year
- CUE 2018
- KORE N/A
- Fundamental
- Price
- CUE $0.74
- KORE $2.50
- Analyst Decision
- CUE Strong Buy
- KORE Hold
- Analyst Count
- CUE 3
- KORE 2
- Target Price
- CUE $3.00
- KORE $2.75
- AVG Volume (30 Days)
- CUE 323.3K
- KORE 9.5K
- Earning Date
- CUE 08-13-2025
- KORE 08-14-2025
- Dividend Yield
- CUE N/A
- KORE N/A
- EPS Growth
- CUE N/A
- KORE N/A
- EPS
- CUE N/A
- KORE N/A
- Revenue
- CUE $7,991,000.00
- KORE $282,254,000.00
- Revenue This Year
- CUE N/A
- KORE $4.66
- Revenue Next Year
- CUE $23.84
- KORE $6.71
- P/E Ratio
- CUE N/A
- KORE N/A
- Revenue Growth
- CUE 13.83
- KORE N/A
- 52 Week Low
- CUE $0.45
- KORE $1.10
- 52 Week High
- CUE $1.99
- KORE $4.88
- Technical
- Relative Strength Index (RSI)
- CUE 51.10
- KORE 55.02
- Support Level
- CUE $0.65
- KORE $2.23
- Resistance Level
- CUE $0.83
- KORE $2.67
- Average True Range (ATR)
- CUE 0.07
- KORE 0.21
- MACD
- CUE 0.01
- KORE 0.02
- Stochastic Oscillator
- CUE 30.43
- KORE 73.78
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.